Active Biotech AB Interim report January – September 2015
- The pivotal CONCERTO clinical Phase 3 study in relapsing remitting MS (RRMS) is proceeding according to plan and results are expected in 2017
- The Phase 2 studies, ARPEGGIO, which will evaluate laquinimod’s potential for treatment of primary progressive MS (PPMS), and LEGATO-HD, for the treatment of Huntington’s disease, are proceeding as planned
- The final results from Active Biotech’s tasquinimod 10TASQ10 Phase 3 trial were presented at the ECC conference and demonstrated that while tasquinimod treatment resulted in a prolonged radiographic progression-free survival (rPFS), 7.0 vs. 4.4 months, the positive effect on rPFS did not translate into an improved OS
- Only commercial activities will be conducted from 2016
|MSEK||July – Sept.||Jan. – Sept.||Jan. – Dec.|
|Loss for the period||-23.4||-56.6||-152.7||-174.5||-231.5|
|Loss per share, before and after dilution (SEK)||-0.26||-0.76||-1.70||-2.33||-3.02|
|Cash and cash equivalents (at the end of the period)||132.4||161.0||328.5|
For further information, please contact:
| Tomas Leanderson,
President and CEO
Tel: +46 (0)46 19 20 95
Hans Kolam, CFO
| Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 00
The report is also available at www.activebiotech.com.
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Globenewswire